Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Shingrix Immunogenicity in UC Patients on Tofacitinib
NCT03591770Phase 4Terminated
- Sponsor
- Boston Medical Center
- Start
- Jul 2019
- Primary completion
- Jul 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of Zoster vaccine recombinant in herpes zoster (HZ), sponsored by Boston Medical Center. Started Jul 2019; status: terminated.
02
Drugs
Zoster vaccine recombinant
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on NCT03591770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03591770.